Shareholder rights law firm Johnson & Weaver, LLP has commenced an
investigation into whether certain officers and directors of Halozyme
Therapeutics, Inc. (NASDAQ: HALO) violated state or federal
laws. Halozyme is a biopharmaceutical company that researches, develops
and commercializes human enzymes.
On April 9, 2014, Halozyme announced that the U.S. Food and Drug
Administration had placed a clinical hold on patient enrollment and
dosing of PEGPH20 in patients with pancreatic cancer. Just a few days
earlier on April 4, 2014, Halozyme issued a statement announcing that
the Phase 2 trial for PEGPH20 would be halted. The suspension of the
trial followed the recommendation of an independent Data Monitoring
Committee (DMC) while it assesses "clinical data that indicates a
possible difference in the thromboembolic event rate between the group
of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus
the group of patients treated with nab-paclitaxel and gemcitabine
without PEGPH20." Since April 4, 2014, Halozyme shares have fallen
$4.02, or 35%, to close at $7.57 on April 17, 2014.
If you are a Halozyme shareholder and are interested in learning more
about the investigation or your legal rights and remedies, please
contact Jim Baker (jimb@johnsonandweaver.com)
at 619-814-4471. If you email, please include your phone number.
Johnson & Weaver, LLP is a nationally recognized shareholder rights law
firm with offices in California and New York. The firm represents
individual and institutional investors in shareholder derivative and
securities class action lawsuits. For more information about the firm
and its attorneys, please visit http://www.johnsonandweaver.com.
Attorney advertising. Past results do not guarantee future outcomes.
Copyright Business Wire 2014